Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 10:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 1,351 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Glioblastoma, Glioma Clear all
Completed Early Phase 1 Interventional

5 Fraction Stereotactic Radiosurgery With Temozolomide for Glioblastoma Multiforme

NCT03291990
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Temozolomide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2021 · Synced Oct 14, 2026, 10:01 PM EDT
Completed Phase 1 Interventional Results available

Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Astrocytoma

NCT00841555
View directory record Official record
Conditions
Glioblastoma Multiforme/Anaplastic Astrocytoma
Interventions
temozolomide, Hypofractionated radiation therapy, Intensity-modulated radiation therapy
Drug · Radiation
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Oct 14, 2026, 10:01 PM EDT
Completed Phase 1Phase 2 Interventional

Chemotherapy in Treating Patients With Progressive or Recurrent Brain Tumors

NCT00012038
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
irofulven
Drug
Lead sponsor
New Approaches to Brain Tumor Therapy Consortium
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
10
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 14, 2026, 10:01 PM EDT
Completed Phase 2 Interventional Results available

Bosutinib in Adult Patients With Recurrent Glioblastoma

NCT01331291
View directory record Official record
Conditions
Glioblastoma
Interventions
bosutinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Oct 14, 2026, 10:01 PM EDT
Completed Phase 1 Interventional

A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme

NCT01752491
View directory record Official record
Conditions
Glioblastoma, GBM, Glioblastoma Multiforme
Interventions
Ascorbate, Temozolomide, Radiation therapy
Drug · Radiation
Lead sponsor
Joseph J. Cullen, MD, FACS
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 14, 2026, 10:01 PM EDT
Completed Phase 1Phase 2 Interventional Results available

First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma

NCT04116658
View directory record Official record
Conditions
Glioblastoma, Adult
Interventions
Multiple dose of EO2401
Biological
Lead sponsor
Enterome
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 14, 2026, 10:01 PM EDT
Completed Not applicable Interventional

Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients

NCT04604158
View directory record Official record
Conditions
Cancer, Cancer Metastatic, Neoplasms, Breast Cancer, Lung Cancer, Glioblastoma, Prostate Cancer, Gynecologic Cancer, Colorectal Cancer, Sarcoma, Kidney Cancer, Bladder Cancer, Lymphoma, Leukemia, Head and Neck Cancer, Pancreas Cancer, Multiple Myeloma, Anxiety, Social Isolation, Stress, Loneliness, Melanoma, Uterine Cancer
Interventions
Elly Mobile Phone Application
Behavioral
Lead sponsor
Gillian Gresham
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Oct 14, 2026, 10:01 PM EDT
Completed Phase 2 Interventional

Biological Therapy in Treating Patients With Glioblastoma Multiforme

NCT00003185
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
autologous tumor cell vaccine, sargramostim, tumor-draining lymph node lymphocyte therapy, cyclophosphamide, conventional surgery
Biological · Drug · Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 1998
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 14, 2026, 10:01 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma

NCT00606008
View directory record Official record
Conditions
Anaplastic Astrocytoma, Glioblastoma
Interventions
Sunitinib Malate
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 19, 2012 · Synced Oct 14, 2026, 10:01 PM EDT
Completed No phase listed Observational

Detecting Malignant Brain Tumor Cells in the Bloodstream During Surgery to Remove the Tumor

NCT00001148
View directory record Official record
Conditions
Astrocytoma, Glioblastoma, Glioma
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 14, 2026, 10:01 PM EDT
Completed Phase 2 Interventional Results available

Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme

NCT00979017
View directory record Official record
Conditions
Glioblastoma Multiforme, Gliosarcoma
Interventions
Avastin, Temozolomide, Irinotecan
Drug
Lead sponsor
Katy Peters
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 19, 2014 · Synced Oct 14, 2026, 10:01 PM EDT
Completed Phase 1 Interventional

Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma

NCT00027625
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
gefitinib, temozolomide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Bethesda, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 14, 2026, 10:01 PM EDT
Terminated Phase 2 Interventional Results available

Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma

NCT03347617
View directory record Official record
Conditions
Glioblastoma
Interventions
Ferumoxytol, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Pembrolizumab
Drug · Other · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 14, 2026, 10:01 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma

NCT02336165
View directory record Official record
Conditions
Glioblastoma
Interventions
Durvalumab, Standard radiotherapy, Bevacizumab
Drug · Radiation · Biological
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 14, 2026, 10:01 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

NCT00305864
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
Interventions
3-Dimensional Conformal Radiation Therapy, Motexafin Gadolinium, Temozolomide
Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
106
States / cities
Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2018 · Synced Oct 14, 2026, 10:01 PM EDT
Completed Phase 2 Interventional Results available

PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation

NCT01402063
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
PPX (CT2103), Temozolomide
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
9
States / cities
La Jolla, California • Scarborough, Maine • Worcester, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 14, 2026, 10:01 PM EDT
Completed Early Phase 1 Interventional

Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide

NCT01907165
View directory record Official record
Conditions
Glioblastoma
Interventions
Temozolomide, Disulfiram, Copper gluconate
Drug · Dietary Supplement
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 20, 2018 · Synced Oct 14, 2026, 10:01 PM EDT
Completed Phase 2 Interventional Results available

Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma

NCT00498927
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
temozolomide, protein expression analysis, reverse transcriptase-polymerase chain reaction, diagnostic laboratory biomarker analysis, immunoenzyme technique
Drug · Genetic · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 14, 2026, 10:01 PM EDT
Completed Phase 2 Interventional

Efficacy of Distant Healing in Glioblastoma Treatment

NCT00029783
View directory record Official record
Conditions
Glioblastoma
Interventions
Distant Healing
Procedure
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 14, 2026, 10:01 PM EDT
Completed Phase 1Phase 2 Interventional

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors

NCT00003461
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Metastatic Cancer, Neuroblastoma
Interventions
surgical procedure, astatine At 211 monoclonal antibody 81C6
Procedure · Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Oct 14, 2026, 10:01 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma

NCT01870726
View directory record Official record
Conditions
c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM
Interventions
INC280, Buparlisib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Oct 14, 2026, 10:01 PM EDT
Recruiting Phase 3 Interventional

Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

NCT05902169
View directory record Official record
Conditions
Glioblastoma, Recurrent Glioblastoma, GBM
Interventions
SonoCloud-9 (SC9), Carboplatin, Lomustine, Temozolomide
Device · Drug
Lead sponsor
CarThera
Industry
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 14, 2026, 10:01 PM EDT
Completed Phase 1 Interventional

Cilengitide in Treating Children With Refractory Primary Brain Tumors

NCT00063973
View directory record Official record
Conditions
Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Ependymoblastoma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Childhood Infratentorial Ependymoma, Childhood Low-grade Cerebellar Astrocytoma, Childhood Low-grade Cerebral Astrocytoma, Childhood Medulloepithelioma, Childhood Mixed Glioma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Brain Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma
Interventions
cilengitide, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Oct 14, 2026, 10:01 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas

NCT01434602
View directory record Official record
Conditions
Brain Tumor, Glioblastoma, Anaplastic Glioma
Interventions
everolimus, sorafenib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Oct 14, 2026, 10:01 PM EDT